A 72 year old woman on holiday in your area consults you four weeks after starting treatment with a non-steroidal anti-inflammatory drug (NSAID) for her painful knee. She complains of “a reaction” to the drug. She says she has had problems with similar drugs previously, but this drug is new and supposedly has fewer side effects. She says she has been feeling weak and giddy and has developed a w...

Moxonidine is a centrally acting antihypertensive agent with high affinity to the imidazolinI1 receptor which induces peripheral sympathetic inhibition reflected by lowering of blood pressure and heart rate (Ernsberger et al. 1993). To a lesser extent it also binds to the α2-receptors whose activation is responsible for side-effects of central antihypertensive drugs such as sedation and dry mou...

OBJECTIVE This paper describes a scoping of adverse event categories and definitions in use across NHS Scotland and makes recommendations about the categories used. METHODS The design involved a network analysis making use of categories and subcategories supplied by 17 different Health Boards via their risk management/clinical governance functions. A total of 128 discrete categories and 1348 ...